Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases.
Medical records for 67 cats with histologically confirmed mammary gland adenocarcinomas treated with adjunctive doxorubicin from June 1994 through December 2002 were reviewed. Data were examined to evaluate factors influencing disease-free interval (DFI) and survival time. The Kaplan-Meier median survival time of cats that received surgery and doxorubicin was 448 days. The Kaplan-Meier median DFI was 255 days. Significant univariate prognostic factors for DFI included histological subtype, completion of initial chemotherapy, development of metastatic disease, and location of metastatic disease. Significant univariate prognostic factors for survival included tumor volume, the development of metastatic disease, and location of metastatic disease.
Novosad
C Andrew
CA
Donaldson-Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, New York, New York 10021, USA.
Bergman
Philip J
PJ
O'Brien
Maura G
MG
McKnight
Joanne A
JA
Charney
Sarah C
SC
Selting
Kim A
KA
Graham
Joanne C
JC
Correa
Stephanie S
SS
Rosenberg
Mona P
MP
Gieger
Tracy L
TL
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002415:Cats; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D053208:Kaplan-Meier Estimate; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000662:veterinary; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin